3,240
Views
69
CrossRef citations to date
0
Altmetric
Research Article

Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer’s disease management

, , &
Pages 3111-3122 | Received 22 Dec 2015, Accepted 09 Feb 2016, Published online: 04 Mar 2016

References

  • Abo El-Khair D, El-Safti F, Nooh H, El-Mehi A. (2014). A comparative study on the effect of high cholesterol diet on the hippocampal CA1 area of adult and aged rats. Anat Cell Biol 47:117–26
  • Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. (2013). Liposome: classification, preparation, and applications. Nanoscale Res Lett 8:102–10
  • Alam S, Khan ZI, Mustafa G, et al. (2012). Development and evaluation of thymoquinone-encapsulated chitosan nanoparticles for nose-to-brain targeting: a pharmacoscintigraphic study. Int J Nanomedicine 7:5705–18
  • Baldrick P. (2010). The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol 56:290–9
  • Bamrungsap S, Zhao Z, Chen T, et al. (2012). Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine 7:1253–71
  • Bethesda M. (1985). Committee on care and use of laboratory animals. Guide for the care and use of laboratory animals. Institute of Laboratory Animals. Resources commission on life sciences. Revised edition. NIH Publication NO. 86-23. Bethesda (MD): National Institute of Health
  • Bhatt R, Singh D, Prakash A, Mishra N. (2015). Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington's disease. disease. Drug Deliv 22:931–9
  • Bhattacharya S, Haertel C, Maelicke A, Montag D. (2014). Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease. PloS One 9:e89454
  • Botner S, Friedman A, Sintov A. (2012). Direct Delivery of intranasal insulin to the brain via microemulsion as a putative treatment of CNS functioning disorders. J Nanomed Nanotechol 3:136
  • Carmo Carreiras M, Mendes E, Jesus Perry M, et al. (2013). The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr Top Med Chem 13:1745–70
  • Chen Y, Liu L. (2012). Modern methods for delivery of drugs across the blood-brain barrier. – barrier. Adv Drug Deliv Rev 64:640–65
  • Contestabile A. (2011). The history of the cholinergic hypothesis. Behav Brain Res 221:334–40
  • Darreh-Shori T, Hellström-Lindahl E, Flores-Flores C, et al. (2004). Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. J Neurochem 88:1102–13
  • Darreh-Shori T, Kadir A, Almkvist O, et al. (2008). Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiol Aging 29:168–84
  • Davidsson P, Blennow K, Andreasen N, et al. (2001). Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci Lett 300:157–60
  • Di Cara B, Panayi F, Gobert A, et al. (2007). Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition: a parallel dialysis and behavioural study in rats. Int J Neuropsychopharmacol 10:383–99
  • Dineley KT, Pandya AA, Yakel JL. (2015). Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci 36:96–108
  • Elgadir MA, Uddin MS, Ferdosh S, et al. (2014). Impact of chitosan composites and chitosan nanoparticle composites on various drug delivery systems: a review. J Food Drug Anal 23:619–29
  • Ellman GL, Courtney KD, Andres V, Featherstone RM. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95
  • Elnaggar YS, Etman SM, Abdelmonsif DA, Abdallah OY. (2015). intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer's disease: optimization, biological efficacy, and potential toxicity. J Pharm Sci 104:3544–56
  • Feldman AT, Wolfe D. (2014). Tissue processing and hematoxylin and eosin staining. Methods Mol Biol 1180:31–43
  • Gage GJ, Kipke DR, Shain W. (2012). Whole animal perfusion fixation for rodents. J Vis Exp 65:35–64
  • Galgatte UC, Kumbhar AB, Chaudhari PD. (2014). Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation. Drug Deliv 21:62–73
  • Geerts H, Guillaumat P-O, Grantham C, et al. (2005). Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res 1033:186–93
  • Goh CW, Aw CC, Lee JH, et al. (2011). Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats. Drug Metab Dispos 39:402–11
  • Hager K, Baseman AS, Nye JS, et al. (2014). Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. disease. Neuropsychiatr Dis Treat 10:391–401
  • Hanafy A, Farid R, El Gamal S. (2015). Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for alzheimer's disease management: preparation and detection in rat brain. Drug Dev Ind Pharm 41:2055–68
  • Haque S, Md S, Fazil M, et al. (2012). Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation. for targetingPharmacokinetic and evaluation. Carbohydr Polym 89:72–9
  • Harkema JR, Carey SA, Wagner JG. (2006). The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol Pathol 34:252–69
  • Hu L, Sun Y, Wu Y. (2013). Advances in chitosan-based drug delivery vehicles. Nanoscale 5:3103–11
  • Illum L, Farraj NF, Davis SS. (1994). Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res 11:1186–9
  • Irie T, Uekama K. (1997). Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 86:147–62
  • Jain A, Gulbake A, Shilpi S, et al. (2013). A new horizon in modifications of chitosan: syntheses and applications. Crit Rev Ther Drug Carrier Syst 30:91–181
  • Kreuter J. (2014). Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv Drug Deliv Rev 71:2–14
  • Leonard AK, Sileno AP, Brandt GC, et al. (2007). In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int J Pharm 335:138–46
  • Li W, Zhou Y, Zhao N, et al. (2012). Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environ Toxicol Pharmacol 34:272–9
  • Lilienfeld S. (2002). Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev 8:159–76
  • Liu H-L, Yang H-L, Lin B-C, et al. (2015). Toxic effect comparison of three typical sterilization nanoparticles on oxidative stress and immune inflammation response in rats. Toxicol Res 4:486–93
  • Lochhead JJ, Thorne RG. (2012). Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 64:614–28
  • Mannens G, Snel C, Hendrickx J, et al. (2002). The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos 30:553–63
  • Md S, Khan RA, Mustafa G, et al. (2013). Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci 48:393–405
  • Md S, Mustafa G, Baboota S, Ali J. (2015). Nanoneurotherapeutics approach intended for direct nose to brain delivery. Drug Dev Ind Pharm 41:1922–34
  • Migliore MM, Vyas TK, Campbell RB, et al. (2010). Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J Pharm Sci 99:1745–61
  • Moffat AC, Osselton MD, Widdop B. (2011). Clarke's analysis of drugs and poisons. London: Pharmaceutical Press
  • Nordberg A, Darreh-Shori T, Peskind E, et al. (2009). Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 6:4–14
  • Ong W-Y, Shalini S-M, Costantino L. (2014). Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders. Curr Med Chem 21:4247–56
  • Ozer J, Ratner M, Shaw M, et al. (2008). The current state of serum biomarkers of hepatotoxicity. Toxicology 245:194–205
  • Priprem A, Chonpathompikunlert P, Sutthiparinyanont S, Wattanathorn J. (2011). Antidepressant and cognitive activities of intranasal piperine-encapsulated liposomes. Adv Biosci Biotechnol 2:108–16
  • Ravi P, Aditya N, Patil S, Cherian L. (2015). Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization. Drug Deliv 22:903–10
  • Salama EEA, Ali AHA, Aldahmash AM, et al. (2013). The role of vitamin e in cerebral hypoxia: an ultrastructural study. Surg Sci 4:100–6
  • Sapan CV, Lundblad RL. (2015). Review of methods for determination of total protein and peptide concentration in biological samples. Proteomics Clin Appl 9:268–76
  • Tumiatti V, Milelli A, Minarini A, et al. (2008). Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer. J Med Chem 51:7308–12
  • Wu H, Li J, Zhang Q, et al. (2012). A novel small Odorranalectin-bearing cubosomes: Preparation, brain delivery and pharmacodynamic study on amyloid treated rats following intranasal administration. Eur J Pharm Biopharm 80:368–78
  • Xu J, Shi H, Ruth M, et al. (2013). Acute toxicity of intravenously administered titanium dioxide nanoparticles in mice. PloS One 8:e70618
  • Yano K, Koda K, Ago Y, et al. (2009). Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice. Br J Pharmacol 156:173–80
  • Yun JW, Yoon JH, Kang BC, et al. (2015). The toxicity and distribution of iron oxide-zinc oxide core-shell nanoparticles in C57BL/6 mice after repeated subcutaneous administration. J Appl Toxicol 35:593–602
  • Zensi A, Begley D, Pontikis C, et al. (2009). Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Control Release 137:78–86
  • Zhang J, Xiong H. 2014. Brain tissue preparation, sectioning, and staining. In: Xiong H, Gendelman H, eds. Current laboratory methods in neuroscience research. New York: Springer, 3–30
  • Zhang X-D, Wu D, Shen X, et al. (2011). Size-dependent in vivo toxicity of PEG-coated gold nanoparticles. Int J Nanomedicine 6:2071–81

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.